NASDAQ:ANCN

Anchiano Therapeutics Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.
$19.85
-3.25 (-14.07 %)
(As of 05/6/2021 12:00 AM ET)
Add
Compare
Today's Range
$19.19
$22.79
50-Day Range
$2.82
$59.00
52-Week Range
$0.51
$10.55
Volume293,816 shs
Average Volume3.15 million shs
Market Capitalization$147.29 million
P/E Ratio132.33
Dividend YieldN/A
Beta0.93

Competitors

Anchiano Therapeutics (NASDAQ:ANCN) Vs. RIGL, ALBO, ICPT, MIRM, VERU, and SIGA

Should you be buying ANCN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Anchiano Therapeutics, including Rigel Pharmaceuticals (RIGL), Albireo Pharma (ALBO), Intercept Pharmaceuticals (ICPT), Mirum Pharmaceuticals (MIRM), Veru (VERU), and SIGA Technologies (SIGA).

Rigel Pharmaceuticals (NASDAQ:RIGL) and Anchiano Therapeutics (NASDAQ:ANCN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings and analyst recommendations.

Insider and Institutional Ownership

82.0% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 9.1% of Anchiano Therapeutics shares are held by institutional investors. 4.7% of Rigel Pharmaceuticals shares are held by insiders. Comparatively, 6.9% of Anchiano Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility & Risk

Rigel Pharmaceuticals has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Comparatively, Anchiano Therapeutics has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.

Profitability

This table compares Rigel Pharmaceuticals and Anchiano Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rigel Pharmaceuticals-26.25%-44.96%-20.08%
Anchiano TherapeuticsN/A36.08%27.40%

Analyst Recommendations

This is a breakdown of recent ratings for Rigel Pharmaceuticals and Anchiano Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rigel Pharmaceuticals01302.75
Anchiano Therapeutics0000N/A

Rigel Pharmaceuticals currently has a consensus target price of $8.3333, indicating a potential upside of 146.55%. Given Rigel Pharmaceuticals' higher probable upside, equities analysts plainly believe Rigel Pharmaceuticals is more favorable than Anchiano Therapeutics.

Earnings and Valuation

This table compares Rigel Pharmaceuticals and Anchiano Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rigel Pharmaceuticals$59.29 million9.70$-66,890,000.00($0.40)-8.45
Anchiano TherapeuticsN/AN/A$-27,120,000.00($3.46)-5.74

Anchiano Therapeutics has lower revenue, but higher earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Anchiano Therapeutics, indicating that it is currently the more affordable of the two stocks.

Albireo Pharma (NASDAQ:ALBO) and Anchiano Therapeutics (NASDAQ:ANCN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.

Volatility and Risk

Albireo Pharma has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Comparatively, Anchiano Therapeutics has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.

Earnings and Valuation

This table compares Albireo Pharma and Anchiano Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Albireo Pharma$9.64 million59.55$-62,720,000.00($5.04)-5.93
Anchiano TherapeuticsN/AN/A$-27,120,000.00($3.46)-5.74

Anchiano Therapeutics has lower revenue, but higher earnings than Albireo Pharma. Albireo Pharma is trading at a lower price-to-earnings ratio than Anchiano Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Albireo Pharma and Anchiano Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Albireo Pharma-751.53%-71.22%-42.91%
Anchiano TherapeuticsN/A36.08%27.40%

Analyst Ratings

This is a breakdown of recent recommendations for Albireo Pharma and Anchiano Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Albireo Pharma00803.00
Anchiano Therapeutics0000N/A

Albireo Pharma currently has a consensus target price of $72.00, indicating a potential upside of 140.72%. Given Albireo Pharma's higher probable upside, equities analysts clearly believe Albireo Pharma is more favorable than Anchiano Therapeutics.

Insider and Institutional Ownership

85.7% of Albireo Pharma shares are owned by institutional investors. Comparatively, 9.1% of Anchiano Therapeutics shares are owned by institutional investors. 5.0% of Albireo Pharma shares are owned by insiders. Comparatively, 6.9% of Anchiano Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Anchiano Therapeutics beats Albireo Pharma on 7 of the 12 factors compared between the two stocks.

Anchiano Therapeutics (NASDAQ:ANCN) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.

Profitability

This table compares Anchiano Therapeutics and Intercept Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Anchiano TherapeuticsN/A36.08%27.40%
Intercept Pharmaceuticals-106.64%-1,973.10%-48.51%

Volatility and Risk

Anchiano Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Anchiano Therapeutics and Intercept Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Anchiano Therapeutics0000N/A
Intercept Pharmaceuticals115802.29

Intercept Pharmaceuticals has a consensus price target of $44.3043, suggesting a potential upside of 158.33%. Given Intercept Pharmaceuticals' higher possible upside, analysts plainly believe Intercept Pharmaceuticals is more favorable than Anchiano Therapeutics.

Institutional & Insider Ownership

9.1% of Anchiano Therapeutics shares are held by institutional investors. Comparatively, 85.8% of Intercept Pharmaceuticals shares are held by institutional investors. 6.9% of Anchiano Therapeutics shares are held by insiders. Comparatively, 23.7% of Intercept Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Anchiano Therapeutics and Intercept Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anchiano TherapeuticsN/AN/A$-27,120,000.00($3.46)-5.74
Intercept Pharmaceuticals$252 million2.26$-344,680,000.00($10.89)-1.57

Anchiano Therapeutics has higher earnings, but lower revenue than Intercept Pharmaceuticals. Anchiano Therapeutics is trading at a lower price-to-earnings ratio than Intercept Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Mirum Pharmaceuticals (NASDAQ:MIRM) and Anchiano Therapeutics (NASDAQ:ANCN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation.

Profitability

This table compares Mirum Pharmaceuticals and Anchiano Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mirum PharmaceuticalsN/A-61.90%-54.46%
Anchiano TherapeuticsN/A36.08%27.40%

Valuation and Earnings

This table compares Mirum Pharmaceuticals and Anchiano Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mirum PharmaceuticalsN/AN/A$-52,550,000.00($4.58)-4.08
Anchiano TherapeuticsN/AN/A$-27,120,000.00($3.46)-5.74

Anchiano Therapeutics is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Mirum Pharmaceuticals has a beta of 2.44, meaning that its stock price is 144% more volatile than the S&P 500. Comparatively, Anchiano Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500.

Insider & Institutional Ownership

72.9% of Mirum Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.1% of Anchiano Therapeutics shares are owned by institutional investors. 45.5% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 6.9% of Anchiano Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for Mirum Pharmaceuticals and Anchiano Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mirum Pharmaceuticals00613.14
Anchiano Therapeutics0000N/A

Mirum Pharmaceuticals presently has a consensus price target of $40.1667, suggesting a potential upside of 115.14%. Given Mirum Pharmaceuticals' higher possible upside, equities research analysts clearly believe Mirum Pharmaceuticals is more favorable than Anchiano Therapeutics.

Summary

Mirum Pharmaceuticals beats Anchiano Therapeutics on 6 of the 11 factors compared between the two stocks.

Veru (NASDAQ:VERU) and Anchiano Therapeutics (NASDAQ:ANCN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership and dividends.

Valuation and Earnings

This table compares Veru and Anchiano Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veru$42.59 million13.19$-18,970,000.00($0.11)-71.00
Anchiano TherapeuticsN/AN/A$-27,120,000.00($3.46)-5.74

Veru has higher revenue and earnings than Anchiano Therapeutics. Veru is trading at a lower price-to-earnings ratio than Anchiano Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

23.3% of Veru shares are held by institutional investors. Comparatively, 9.1% of Anchiano Therapeutics shares are held by institutional investors. 26.1% of Veru shares are held by company insiders. Comparatively, 6.9% of Anchiano Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Veru and Anchiano Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Veru-44.55%-23.72%-13.80%
Anchiano TherapeuticsN/A36.08%27.40%

Volatility and Risk

Veru has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, Anchiano Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Veru and Anchiano Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Veru00503.00
Anchiano Therapeutics0000N/A

Veru presently has a consensus price target of $19.20, suggesting a potential upside of 145.84%. Given Veru's higher probable upside, equities analysts plainly believe Veru is more favorable than Anchiano Therapeutics.

Summary

Veru beats Anchiano Therapeutics on 7 of the 12 factors compared between the two stocks.

SIGA Technologies (NASDAQ:SIGA) and Anchiano Therapeutics (NASDAQ:ANCN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for SIGA Technologies and Anchiano Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SIGA Technologies0000N/A
Anchiano Therapeutics0000N/A

Profitability

This table compares SIGA Technologies and Anchiano Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SIGA Technologies34.62%37.31%25.33%
Anchiano TherapeuticsN/A36.08%27.40%

Institutional and Insider Ownership

29.3% of SIGA Technologies shares are held by institutional investors. Comparatively, 9.1% of Anchiano Therapeutics shares are held by institutional investors. 3.9% of SIGA Technologies shares are held by company insiders. Comparatively, 6.9% of Anchiano Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares SIGA Technologies and Anchiano Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SIGA Technologies$26.74 million20.85$-7,240,000.00N/AN/A
Anchiano TherapeuticsN/AN/A$-27,120,000.00($3.46)-5.74

SIGA Technologies has higher revenue and earnings than Anchiano Therapeutics.

Volatility and Risk

SIGA Technologies has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, Anchiano Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500.

Summary

SIGA Technologies beats Anchiano Therapeutics on 5 of the 9 factors compared between the two stocks.


Anchiano Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.38-3.6%$575.01 million$59.29 million-22.53Earnings Announcement
Analyst Revision
News Coverage
Gap Up
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$29.91-0.9%$574.09 million$9.64 million-4.87Earnings Announcement
News Coverage
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$17.15-0.8%$568.73 million$252 million-1.75Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$18.67-5.2%$568.35 millionN/A-5.43Earnings Announcement
News Coverage
Veru logo
VERU
Veru
1.4$7.81-5.8%$561.63 million$42.59 million-27.89Upcoming Earnings
Analyst Revision
Gap Up
SIGA Technologies logo
SIGA
SIGA Technologies
0.3$7.33-0.0%$557.56 million$26.74 million18.33News Coverage
Inventiva logo
IVA
Inventiva
0.0$14.40-0.1%$556.27 millionN/A0.00
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$8.55-4.7%$555.78 million$57.49 million-7.18Earnings Announcement
Analyst Downgrade
News Coverage
Gap Up
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$11.36-7.2%$552.13 millionN/A-5.83Earnings Announcement
Analyst Downgrade
News Coverage
Gap Up
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.0$41.65-2.9%$546.41 million$195.89 million119.00Upcoming Earnings
Analyst Downgrade
Decrease in Short Interest
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$14.09-2.6%$516.16 millionN/A-4.06Upcoming Earnings
Analyst Revision
News Coverage
XBiotech logo
XBIT
XBiotech
1.0$17.04-0.1%$510.91 millionN/A1.18Upcoming Earnings
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.6$9.54-1.2%$509.19 millionN/A-3.83Analyst Downgrade
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$20.46-2.3%$508.80 millionN/A-8.06Upcoming Earnings
News Coverage
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$4.83-3.3%$499.64 million$102.31 million7.21Upcoming Earnings
News Coverage
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.8$3.12-3.5%$498.91 million$335 million-1.05Upcoming Earnings
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.81-1.8%$494.14 million$22.27 million-4.32Upcoming Earnings
Altimmune logo
ALT
Altimmune
1.8$13.27-2.6%$492.98 million$5.80 million-6.67Upcoming Earnings
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$11.58-3.0%$490.14 million$25 million-17.82
Verastem logo
VSTM
Verastem
1.1$2.85-0.0%$489.25 million$17.46 million-2.02Analyst Revision
News Coverage
89bio logo
ETNB
89bio
1.6$24.17-0.2%$484.25 millionN/A-4.79Upcoming Earnings
Increase in Short Interest
Analyst Revision
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.4$5.82-2.2%$482.64 million$56.50 million0.00News Coverage
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.08-2.9%$479.60 million$109.33 million-2.26Upcoming Earnings
Analyst Revision
News Coverage
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.17-3.5%$477.66 million$59.22 million40.85Upcoming Earnings
ANI Pharmaceuticals logo
ANIP
ANI Pharmaceuticals
1.5$38.60-9.3%$477.29 million$206.55 million-19.40High Trading Volume
Analyst Revision
News Coverage
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$5.90-2.2%$460.79 millionN/A-12.04Analyst Downgrade
Analyst Revision
Akouos logo
AKUS
Akouos
1.7$13.17-1.4%$453.69 millionN/A0.00
Applied Therapeutics logo
APLT
Applied Therapeutics
1.8$17.43-2.2%$453.37 millionN/A-3.66Upcoming Earnings
Provention Bio logo
PRVB
Provention Bio
1.6$7.14-1.8%$452.50 millionN/A-4.79Earnings Announcement
Analyst Report
Analyst Revision
Sesen Bio logo
SESN
Sesen Bio
1.2$2.67-1.9%$452.26 millionN/A-6.07Upcoming Earnings
AC Immune logo
ACIU
AC Immune
1.3$6.15-1.8%$446.82 million$111.75 million-6.83
Forte Biosciences logo
FBRX
Forte Biosciences
1.7$32.64-2.0%$441.03 million$40,000.00-1.42Upcoming Earnings
News Coverage
MedAvail logo
MDVL
MedAvail
1.9$13.50-3.6%$431.27 million$1.03 million-3.31Upcoming Earnings
Athenex logo
ATNX
Athenex
1.6$4.60-7.0%$430.07 million$101.23 million-3.15Earnings Announcement
Unusual Options Activity
Gap Down
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.09-1.8%$428.58 million$49.65 million-1.54Earnings Announcement
News Coverage
Geron logo
GERN
Geron
1.4$1.33-0.8%$423.65 million$460,000.00-3.80Upcoming Earnings
Seelos Therapeutics logo
SEEL
Seelos Therapeutics
1.3$5.37-4.3%$421.60 million$380,000.000.00News Coverage
Nature's Sunshine Products logo
NATR
Nature's Sunshine Products
0.9$20.66-1.1%$408.99 million$362.21 million24.89Decrease in Short Interest
News Coverage
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$11.25-0.1%$403.62 million$58.12 million-13.08Analyst Upgrade
High Trading Volume
Analyst Revision
News Coverage
Gap Up
Oncorus logo
ONCR
Oncorus
1.7$15.65-1.7%$401.42 millionN/A0.00Earnings Announcement
Insider Selling
High Trading Volume
Analyst Revision
News Coverage
Gap Down
DURECT logo
DRRX
DURECT
1.4$1.76-2.3%$400.14 million$29.56 million-35.19Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Evolus logo
EOLS
Evolus
1.5$9.14-5.1%$399.77 million$34.92 million-4.50Upcoming Earnings
Analyst Upgrade
Increase in Short Interest
Analyst Revision
Spero Therapeutics logo
SPRO
Spero Therapeutics
1.5$13.42-5.0%$395.94 million$18.15 million-3.16Earnings Announcement
Analyst Revision
News Coverage
Puma Biotechnology logo
PBYI
Puma Biotechnology
1.3$9.79-1.1%$395.14 million$272.30 million-6.85Earnings Announcement
Analyst Revision
News Coverage
Hookipa Pharma logo
HOOK
Hookipa Pharma
1.2$15.10-0.7%$392.52 million$11.94 million-9.21Upcoming Earnings
BeyondSpring logo
BYSI
BeyondSpring
1.2$9.98-0.4%$390.64 millionN/A-4.89Analyst Revision
Fortress Biotech logo
FBIO
Fortress Biotech
1.6$3.94-2.8%$383.18 million$36.63 million-4.64Upcoming Earnings
Analyst Revision
News Coverage
UroGen Pharma logo
URGN
UroGen Pharma
1.8$18.22-1.0%$380.74 million$20,000.00-2.85Upcoming Earnings
News Coverage
Gap Up
Inozyme Pharma logo
INZY
Inozyme Pharma
1.7$16.14-1.4%$378.87 millionN/A0.00Analyst Revision
News Coverage
Gap Down
MEI Pharma logo
MEIP
MEI Pharma
1.7$3.31-0.3%$372.47 million$28.91 million-5.52Earnings Announcement
News Coverage
This page was last updated on 5/8/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.